Revolutionary Immunotherapy Slows Alzheimer's Progression and Introduces Innovative Drug Delivery System

Scientists are developing a new approach to treat Alzheimer's disease by targeting the immune system. The use of antibodies that can bind to abnormal protein clumps in the brain shows promise in slowing the progression of the disease. These antibodies have been found to reduce amyloid deposits and slow decline in the earliest symptomatic stages of Alzheimer's. While two antibodies have already been FDA approved, caution is needed due to potential side effects and the need for early treatment. Further research and investment are necessary to effectively treat Alzheimer's.